Treatment of favourable-risk metastatic kidney cancer

The treatment of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC) has been dramatically changed with the introduction of immune checkpoint inhibitors (immunotherapy) as a first-line of treatment after surgery. However, it is less clear whether immunotherapy benefits patients with favourable-risk disease in the same way. A debate between experts at the International […]

read more

Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

A recent phase II clinical trial has shown that combined use of a PD-1 inhibitor and a PD-L1 inhibitor proved no more beneficial than anti-PD-1 treatment alone in metastatic renal cell carcinoma (RCC) patients who had already been treated with targeted therapy. There was no significant difference in the primary endpoint of the study, which […]

read more

Real world use of targeted therapies in war veterans with kidney cancer

A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]

read more

Real world use of pazopanib after immunotherapy for advanced kidney cancer

A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more

SBRT in combination with systemic treatment for metastatic kidney cancer

Two recent studies have looked at the effect of stereotactic body radiotherapy (SBRT) in combination with tyrosine kinase inhibitors or immune checkpoint inhibitors on renal cell carcinoma (RCC) metastases and survival. In the first study, a total of 17 patients with stable metastatic RCC were assessed. The effect of SBRT on the target metastasis was […]

read more
Showing 1 to 6 of 714 results